Perhaps sampling of carcinomas has so far been too limited to identify heterogeneous KRAS mutations in relatively small clones, or, alternatively, during the progression from adenomas to carcinoma a clonal sweeping event might establish a founder KRAS mutant clone. The gene discussed is KRAS; the disease is carcinoma.